Literature DB >> 6201067

Thirty years of supplying the missing link. History of gamma globulin therapy for immunodeficient states.

J M Dwyer.   

Abstract

Man has been injecting himself with gamma globulin for almost 100 years. As a result, both the benefits and the hazards of such therapy have been convincingly demonstrated. For 30 years physicians have realized that one group of patients must receive regular injections of this material to avoid death from overwhelming bacterial infections. The health of subjects with congenital or acquired hypogammaglobulinemia is directly related to the successful administration of adequate amounts of immunoglobulin G (IgG). Three phases are easily recognizable when examining the history of how physicians have accomplished such replacement therapy. Initially, therapy was limited to frequent and painful intramuscular injections of concentrated immune serum globulin. In some patients, the administration of monthly infusions of fresh plasma from "buddies" supplied a better approach. Now, the elusive goal of having a concentrated form of gamma globulin suitable for intravenous administration has been reached. Such preparations are revolutionizing the treatment of human immune deficiencies and expanding the therapeutic potential of gamma globulin itself.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6201067     DOI: 10.1016/0002-9343(84)90319-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

1.  Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia.

Authors:  J E Pennington; G J Small; M E Lostrom; G B Pier
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

2.  Hypothesis: selective ineffective humoral immune responsiveness as a possible cause of certain chronic inflammatory disorders. Theoretical considerations and rationale for treatment.

Authors:  A Hässig; H Cottier
Journal:  Klin Wochenschr       Date:  1986-05-02

3.  Administration of intravenous immunoglobulin in two children with hypogammaglobulinaemia due to protein losing enteropathy.

Authors:  C De Giacomo; G Maggiore; M S Scotta; A G Ugazio
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

Review 4.  Hypogammaglobulinemia: therapeutic rationale.

Authors:  A A Long; J A Denburg; P B Dent
Journal:  CMAJ       Date:  1987-11-01       Impact factor: 8.262

5.  Serum immunoglobulins to endotoxin core glycolipid: establishment of normal concentrations.

Authors:  S K Jackson; J Parton; G Shortland; J M Stark; E N Thompson
Journal:  Arch Dis Child       Date:  1990-07       Impact factor: 3.791

Review 6.  Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes.

Authors:  S A Schwartz
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

Review 7.  Intravenous immune globulins. A review of their uses in selected immunodeficiency and autoimmune diseases.

Authors:  B Pirofsky; D M Kinzey
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

8.  Localised pulmonary resection for bronchiectasis in hypogammaglobulinaemic patients.

Authors:  A J Cohen; C Roifman; J Brendan; M Mullen; B Reid; G Weisbrod; G P Downey
Journal:  Thorax       Date:  1994-05       Impact factor: 9.139

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.